These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12380149)

  • 1. [Maintaining the full benefit of statins. Therapy start 10 years earlier?].
    MMW Fortschr Med; 2002 Aug; 144(33-34):55. PubMed ID: 12380149
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New LDL goals: even lower?
    Johns Hopkins Med Lett Health After 50; 2004 Jul; 17(5):1-2, 7. PubMed ID: 15233099
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lowering of cholesterol. What role is played by the choice of statins?].
    März W
    MMW Fortschr Med; 2004 Sep; 146(35-36):55. PubMed ID: 15540544
    [No Abstract]   [Full Text] [Related]  

  • 6. Study suggests statins for diabetics with healthy LDL cholesterol levels.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Sep; 15(18):1-2, 6-7. PubMed ID: 15452942
    [No Abstract]   [Full Text] [Related]  

  • 7. Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
    Athyros VG; Tziomalos K; Karagiannis A; Wierzbicki AS; Mikhailidis DP
    Curr Opin Cardiol; 2010 Jul; 25(4):406-10. PubMed ID: 20375883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 12. [Following the ASCOT Study. A statin for every hypertensive patient?].
    MMW Fortschr Med; 2003 Apr; 145(16):8. PubMed ID: 14606391
    [No Abstract]   [Full Text] [Related]  

  • 13. [Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
    Nissen S
    MMW Fortschr Med; 2004 Mar; 146(13):65. PubMed ID: 15219143
    [No Abstract]   [Full Text] [Related]  

  • 14. Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
    Hackam DG
    CMAJ; 2003 Jun; 168(13):1689. PubMed ID: 12821623
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
    Schmermund A; Achenbach S; Budde T; Buziashvili Y; Förster A; Friedrich G; Henein M; Kerkhoff G; Knollmann F; Kukharchuk V; Lahiri A; Leischik R; Moshage W; Schartl M; Siffert W; Steinhagen-Thiessen E; Sinitsyn V; Vogt A; Wiedeking B; Erbel R
    Circulation; 2006 Jan; 113(3):427-37. PubMed ID: 16415377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
    Harv Heart Lett; 2004 May; 14(9):3. PubMed ID: 15153372
    [No Abstract]   [Full Text] [Related]  

  • 17. [Decreasing blood lipids for prevention of coronary heart disease--discussion of the "permissive LDL level". Diagnostic imaging facilitates therapeutic decision].
    MMW Fortschr Med; 2001 Mar; 143(13):48-9. PubMed ID: 11332020
    [No Abstract]   [Full Text] [Related]  

  • 18. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
    MMW Fortschr Med; 2005 Mar; 147(12):4. PubMed ID: 15832778
    [No Abstract]   [Full Text] [Related]  

  • 20. Atorvastatin.
    Hyatt PJ
    Br J Hosp Med; 1997 Oct 1-14; 58(7):333-6. PubMed ID: 9509055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.